不同方法治疗新诊断2型糖尿病的效果比较

Abstract
Figure/Table
References (16)
Related Citation (2)

Download: PDF (0 KB) HTML (27 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo compare the efficacy and safety between Glargine Insulin plus Melformin and Insulin Aspart 30 Injections in newly diagnosed type 2 diabetes mellitus patients(T2DM).MethodsA total of 68 newly diagnosed type 2 diabetes mellitus patients who hospitalized in the endocrinology department of our hospital from October 2015 to October 2016 were selected as subjects and were randomized into Glargine Insulin plus Melformin group(Gla+Mel group)and Insulin Aspart 30 Injections group(Asp 30 group),34 cases in each group,and they were treated for four weeks.The blood glucose,the blood glucose up to standard time,the incidence of hypoglycemia and the patient satisfaction rate were compared between the two groups.ResultsAfter 4 weeks of treatment,the FBG,2 h PG and HbA1c of the two groups were significantly lower than those in the group before treatment,and the differences were statistically significant(P＜0.05).The FBG,2 h PG and HbA1c of patients in Gla+Mel group were compared with Asp 30 group,and the differences were not statistically significant(P＞0.05).The blood glucose up to standard time of patients in the two group were compared,and the difference was not statistically significant(P＞0.05).The incidence of hypoglycemia in Gla+Mel group was significantly lower than that in the Asp 30 group,and the difference was statistically significant(P＜0.05).The satisfaction rate of patients in the Gla+Mel group was significantly higher than that of Asp 30 group,and the difference was statistically significant(P＜0.05).ConclusionFor newly diagnosed type 2 diabetic mellitus patients,Glargine Insulin plus Melformin could control blood glucose well,the incidence of hypoglycemia is low,and the satisfaction of treatment is high.

Key words： Type 2 diabetes mellitus Glargine Insulin Melformin Insulin Aspart 30 Injections

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Sa
	SHI Yi-shan

Cite this article:

ZHAO Sa,SHI Yi-shan. Effect comparison of different methods in the treatment of newly diagnosed type 2 diabetes mellitus[J]. 中国当代医药, 2018, 25(3): 98-100.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I3/98

[1]	佚名.IDF全球糖尿病概览（第6版）[J].中国全科医学，2014，（26）：3124.
[2]	Yang W，Lu J，Weng J，et al.Prevalence of diabetes among menandwomeninChina[J].NEnglJMed，2010，362（12）：1090-1101.
[3]	黄卫华，邱增新，曾鑫.胰岛素泵短期持续皮下注射胰岛素类似物对初诊2型糖尿病的临床疗效分析[J].中国药物经济学，2014，13（5）：63.
[4]	周薇霞，俞宁娟，沈丰庆，等.推广胰岛素治疗适宜技术对社区糖尿病管理模式的影响[J].现代实用医学，2014，26（5）：561-563.
[5]	中华医学会糖尿病学分会.中国2型糖尿病防治指南[M].2010版.北京：北京大学医学出版社，2011：11.
[6]	徐丽玲，韦文合，梁慧慧.2型糖尿病患者慢性并发症相关危险因素分析及防治研究[J].中外医学研究，2016，14（21）：9-10.
[7]	庞翠平.胰岛素泵治疗初诊2型糖尿病临床疗效观察[J].中国药物与临床，2015，2（15）：253-254.
[8]	王小丽.影响社区糖尿病患者药物治疗依从性的因素及护理[J].现代实用医学，2016，28（1）：114-115.
[9]	李延兵.2型糖尿病病程进展与胰岛素强化治疗[J].中国糖尿病杂志，2016，24（3）：286-288.
[10]	刘烨，王艳荣.基础胰岛素联合口服降糖药-长病程2型糖尿病患者胰岛素强化治疗后的可选之路[J].药品评价，2017，14（7）：9-13.
[11]	American Diabetes Association.Standards of medical care in diabetes[J].Diabetes Care，2017，40（S1）：1-135.
[12]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013年版）[J].中华糖尿病杂志，2014，6（7）：447-498.
[13]	母义明，纪立农，宁光，等.二甲双胍临床应用专家共识[J].中国糖尿病杂志.2014，22（8）：673-681.
[14]	李萌，纪立农.二甲双胍在2型糖尿病患者中的安全性[J].中国糖尿病杂志，2014，4（22）：289-292.
[16]	杨颖，田源，高凌.口服降糖药血糖控制不佳的2型糖尿病加用地特胰岛素或甘精胰岛素的疗效比较[J].实用药物与临床，2012，15（3）：140-142.
[15]	Wang CZ，Pan X.Profile of vildagliptin in type 2 diabetes：efficacy，safety，and patientacceptability[J].Ther Clin Risk Manag，2013，9（20）：247-257.